News
June
Jun.28, 2024
Release
Shionogi Presented New Clinical Data on the COVID-19 Treatment Ensitrelvir
Jun.20, 2024
Release
Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
Jun.14, 2024
Notice
Transcript of R&D Day Follow-up Meeting
Jun.11, 2024
Notice
Transcript of R&D Day 2024
Jun.06, 2024
Notice
Presentation Materials for R&D Day
Jun.06, 2024
Release
Option Agreement with Cilcare for Development Compounds Addressing Hearing Loss
Jun.04, 2024
Release
Shionogi Awarded the Imperial Invention Prize
May
May.31, 2024
Release
Position and Policy Regarding Reduction of the Investment Unit
May.16, 2024
Notice
Transcript of FY2023 Financial Results
May.13, 2024
Notice
Presentation Materials for FY2023 financial results
May.13, 2024
Notice
Financial Results and supplement for FY2023
April
Apr.25, 2024
Release
Notice of Revisions to Dividend Forecasts (Dividend Increase)
Apr.08, 2024
Release
Regarding Support for Earthquake Relief Efforts in Eastern Taiwan
March
February
Feb.22, 2024
Release
FETROJA® (cefiderocol) Approved by TFDA in Taiwan
Feb.02, 2024
Notice
Transcript of the FY2023 3Q Financial Results Conference
January
Jan.31, 2024
Notice
Financial Results and supplement for FY2023 3Q
Jan.31, 2024
Notice
Presentation Materials for FY2023 3Q financial results
Jan.25, 2024
Release
Notice of Investment Agreement with Niremia Collective
Jan.05, 2024
Notice
Regarding the "the ‘2024 (Reiwa 6) Noto Peninsula Earthquake" Disaster Situation